“Please take notes if you want to, but I’m going to give you an audio-recording of this meeting to take home”

For the majority of newly diagnosed prostate cancer patients, the first meeting with their physician after diagnosis presents them with more information than they are able to assimilate easily … and many patients don’t have the necessary scientific or medical background to understand everything they are being told — even if they hear it all. … READ MORE …

Using the modified poliovirus to treat prostate cancer

For the benefit of those who saw (or heard about but did not see) the “60 Minutes” program last night dealing with the use of modified poliovirus in the treatment of patients with recurrent glioblastoma (a form of brain cancer), let us be very clear. … READ MORE …

Transrectal biopsy and the increasing risk for procedure-related infection

According to a paper presented at the recent meeting of the European Association of Urology in Madrid, Spain, there seems to be a significant and ongoing rise in the global risk for infections associated with prostate biopsy (and particularly with the transrectal prostate biopsy). … READ MORE …

Use of CTCs to assess response to abiraterone acetate at 12 weeks on therapy

Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …

After 10 years, risk of prostate cancer-specific mortality lower for high-risk patients

A paper presented at the annual meeting of the European Association of Urology (EAU) suggests that high-risk prostate cancer patients < 60 years of age at the time of radical prostatectomy are more likely to die from their cancer than from other causes during the first 10 years after their surgery. But after that, other causes of death become more likely. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!

A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers